NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.383) was uploaded to the NHS England Website on Tuesday 20, January 2026.
The following changes have been introduced:
Nivolumab (NIV25)
Nivolumab plus chemotherapy for neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untreated UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non- small cell lung cancer AND who are candidates for potentially curative surgery where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Abiraterone acetate (ABI5)
For the treatment of high-risk, hormone sensitive, non-metastatic prostate cancer where the following criteria have been met
Recommended for routine commissioning - straight into section B of the list
Avelumab (AVE4)
Avelumab monotherapy for the maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have just completed and not progressed on 1st line platinum-containing combination chemotherapy where the following criteria have been met
Treatment criteria (#2, 4 and 11) updated; ‘TA’ column updated, ‘Date of NICE Final Guidance’ column updated; ‘Date Baseline Funding started’ column updated
Bevacizumab at a dose of 7.5mg/Kg (BEV10)
As MAINTENANCE monotherapy for patients with stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma where the following criteria have been met Note: there is a separate form BEV3 for the use of bevacizumab at a dose of 7.5mg/Kg in combination with 1st line chemotherapy AS INDUCTION TREATMENT for advanced ovarian cancer Note: there is a separate form BEV9 for the use of bevacizumab at a dose of 15mg/Kg in combination with 1st line chemotherapy AS INDUCTION TREATMENT for advanced ovarian cancer Note: if an application is being made for the 1st line maintenance combination
Treatment criteria (#2, 4 and 6) updated
Olaparib in combination with hormone therapy (OLAP6)
As adjuvant treatment of high-risk HORMONE RECEPOR POSITIVE HER 2 NEGATIVE early breast cancer treated with neoadjuvant or adjuvant chemotherapy and definitive local therapy in patients with a deleterious or suspected deleterious germline BRCA mutation where the following criteria have been met
Treatment criterion (#7) updated
Pembrolizumab in combination with carboplatin and paclitaxel (PEMB10)
For the first line treatment of PD-L1 positive or negative locally advanced or metastatic squamous non-small cell lung cancer where the following criteria have been met
Treatment criteria (#2, 7 and 12) updated
Durvalumab in combination with chemotherapy (DUR3)
For the treatment of neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untreated UICC/AJCC 8th edition stage or IIB or IIIA or N2 only IIIB non-small cell lung cancer AND who are candidates for potentially curative surgery where the following criteria have been met
Treatment criterion (#5 and 14) updated; Treatment criteria (#2, 6 and 16) removed
Pembrolizumab in combination with chemotherapy (PEMB30)
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untreated UICC/AJCC 8th edition stage or IIB or IIIA or N2 only IIIB non-small cell lung cancer AND who are candidates for potentially curative surgery where the following criteria have been met
Treatment criterion (#5 and 14) updated; Treatment criteria (#2, 6, 8 and 17) removed